MedTrace Logo

Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine

NCT04078698 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-09-04

No results posted yet for this study

Summary

Documentation of the safety and effectiveness profile of the CE-labelled immunoadsorber GLOBAFFIN® in clinical routine according to their intended use.

Conditions

Interventions

DEVICE

Immunoadsorber GLOBAFFIN®

Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease

Sponsors & Collaborators

  • Alcedis GmbH

    collaborator INDUSTRY

  • Fresenius Medical Care Deutschland GmbH

    lead INDUSTRY

Principal Investigators

  • Jan T. Kielstein, Prof. Dr. · Academic Teaching Hospital Braunschweig

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2025-05-30
Completion
2025-08-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04078698 on ClinicalTrials.gov